Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog designed to stimulate endogenous growth hormone production through a physiologic mechanism. Clinically, it has been studied for its ability to reduce visceral adipose tissue, support lean body composition, and improve metabolic profiles in targeted patient populations. Its selective action on growth hormone pathways allows for enhanced fat metabolism without broadly affecting other endocrine systems.
In practice, Tesamorelin may be integrated into physician-supervised protocols addressing metabolic health, body composition optimization, and age-related changes in tissue distribution. Its use should be individualized based on patient assessment, monitored for efficacy and safety, and implemented in compliance with regulatory and clinical guidelines.
